Rite Aid Corporation Earnings: Is Recent Growth Sustainable?

Rite Aid has made a solid recovery, but can it keep up with Walgreen and CVS?

Jun 18, 2014 at 6:00PM

On Thursday, Rite Aid (NYSE:RAD) will release its quarterly report. Shareholders remain encouraged by the huge gains the stock has made over the past year. Despite skepticism among those who believed that the drugstore chain could never compete effectively against Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS), Rite Aid has made substantial progress in making itself a viable long-term player in the industry.

For years, many investors believed that Rite Aid wouldn't be able to survive, with substantial amounts of debt and a smaller network of stores than CVS Caremark or Walgreen. But the underdog drugstore chain has aggressively moved forward with efforts to boost its margins and improve its image, and profitable results for two straight years have defied naysayers and convinced many that Rite Aid's turnaround story is real. Let's take an early look at what's been happening with Rite Aid over the past quarter and what we're likely to see in its report.


Stats on Rite Aid

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$6.43 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

How far can Rite Aid earnings climb?
In recent months investors have had mixed views on Rite Aid earnings, cutting their May-quarter estimates by $0.03 per share but boosting their fiscal 2016 projections by about 4%. The stock has reflected overall enthusiasm for the company, though, gaining another 7% since mid-March.

Rite Aid's fiscal fourth-quarter results in April showed investors just how far the company has come. Profits were much higher than expected, with same-store sales gains of 2.1% resulting from a 3.5% boost in pharmacy comps. In addition, projections for the full fiscal year look promising, with comps expected to rise between 2.5% and 4.5% and large gains seen for adjusted operating earnings as well.


Source: Rite Aid.

Yet just earlier this month, Rite Aid gave investors pause about how much further it could climb. The company said May same-store sales rose 3.5%, but it cut its profit expectations because of higher drug costs. Even though the reduction in full-year guidance was just $0.01 to $0.02 per share, Rite Aid stock plunged in response as some momentum investors saw a chance that the good times were coming to an end.

Still, Rite Aid's recovery has been impressive because of the scope of improvements the company has made. Even as Walgreen has managed to win some of its customers back from Rite Aid after a pharmacy-benefit dispute forced many Walgreen customers to defect to Rite Aid and CVS, Rite Aid has benefited greatly from the rise of generic drugs and the higher margins they give its pharmacy business. With a recent deal to get all of its generic drugs from a single source, Rite Aid should see even greater efficiency improvements, with less need to stock substantial drug inventories, freeing up working capital for other uses.

Now, Rite Aid is moving toward fostering its own growth. In April, Rite Aid announced it would purchase Texas-area clinic operator RediClinic, furthering the drugstore chain's efforts to broaden its mission to incorporate more aspects of health care and answering similar moves from Walgreen and CVS Caremark on the clinic front. In addition, store remodeling efforts to recast its drugstores as wellness-oriented stores has allowed Rite Aid to expand into other product lines, ranging from fitness apparel and equipment to specialized nutritional products and foods. Rite Aid's loyalty program has also been a source of growth, with much better rewards than CVS and Walgreen offer, helping to encourage long-term patronage among customers.

In the Rite Aid earnings report, watch to see how well the company is doing at making its store-format transition and taking advantage of the opportunities in its clinic business. With strong competition from CVS Caremark and Walgreen and so much up in the air on the health-care front, Rite Aid has a chance to set trends that could take it forward for years into the future.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Click here to add Rite Aid to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information